Joensuu H, Alanen K, Falkmer U G, Klemi P, Nordling S, Remvikos Y, Toikkanen S
Department of Oncology, Turku University Central Hospital, Finland.
Int J Cancer. 1992 Nov 11;52(5):701-6. doi: 10.1002/ijc.2910520506.
A series of 327 breast cancers was analyzed for DNA ploidy by flow cytometry from paraffin-embedded tissue, and the resulting DNA histograms were classified independently by 6 researchers in the field as DNA diploid (Di), aneuploid (An), tetraploid (Te), multiploid (Mu), or technically uninterpretable. The frequency of diploid, aneuploid, tetraploid and multiploid cancers varied from 28 to 41%, 33 to 49%, 8 to 21% and 2 to 6%. According to the scale Di-An-Te-Mu, DNA ploidy was not significantly associated with breast-cancer mortality by 2 classifiers, but if DNA euploid cancers (Di+Te) were tested against non-euploid, or diploid cancers against non-diploid, all classifiers found DNA euploid and diploid cancers to have better prognosis. Mortality associated with diploid or tetraploid cancers decreased with improving histogram quality and increasing uniformity of classification, whereas that associated with aneuploid cancers remained unaltered. Among the cases where all classifiers agreed on ploidy, tetraploid, diploid and aneuploid cancers were associated with 100%, 88% and 68% 5-year survival rates. In this sub-set the S-phase fraction and possibly DNA ploidy were independent prognostic factors, together with histological grade, axillary node status, and primary tumor size.
通过流式细胞术对327例石蜡包埋组织的乳腺癌进行DNA倍体分析,并由该领域的6名研究人员将所得的DNA直方图独立分类为DNA二倍体(Di)、非整倍体(An)、四倍体(Te)、多倍体(Mu)或技术上无法解释的类型。二倍体、非整倍体、四倍体和多倍体癌症的频率在28%至41%、33%至49%、8%至21%和2%至6%之间变化。根据Di-An-Te-Mu量表,有2名分类人员认为DNA倍体与乳腺癌死亡率无显著相关性,但如果将DNA整倍体癌症(Di+Te)与非整倍体癌症进行比较,或将二倍体癌症与非二倍体癌症进行比较,所有分类人员均发现DNA整倍体和二倍体癌症的预后较好。与二倍体或四倍体癌症相关的死亡率随着直方图质量的提高和分类一致性的增加而降低,而与非整倍体癌症相关的死亡率则保持不变。在所有分类人员对倍体分类一致的病例中,四倍体、二倍体和非整倍体癌症的5年生存率分别为100%、88%和68%。在这个亚组中,S期分数以及可能的DNA倍体与组织学分级、腋窝淋巴结状态和原发肿瘤大小一起,都是独立的预后因素。